|
EP1355912A1
|
|
Ligands and their use
|
|
WO02053536A1
|
|
Chiral scaffolds and their preparation
|
|
GB0129112D0
|
|
Chiral ligands for asymmetric catalysis
|
|
GB0128512D0
|
|
Compounds and their therapeutic use
|
|
GB0124713D0
|
|
Catalysts for asymmetric reactions
|
|
GB0120167D0
|
|
Asymmetric hydrogenation
|
|
GB0119955D0
|
|
Ligands and their use
|
|
AU7089201A
|
|
Ruthenium complexes and their use in asymmetric hydrogenation
|
|
GB0113669D0
|
|
Crystallisation and asymmetric hydrogenation
|
|
GB0113667D0
|
|
Process for the preparation of endo-5-norbornene-2-ol
|
|
CA2410410A1
|
|
Chiral ligands for asymmetric catalysis
|
|
CA2414049A1
|
|
Ruthenium-diphosphine complexes and their use as catalysts
|
|
GB0105742D0
|
|
Complexes and their use
|
|
GB0101458D0
|
|
Chiral ligands for asymmetric catalysis
|
|
GB0101462D0
|
|
Ligands and their use
|
|
GB0101461D0
|
|
Novel phosphine
|
|
GB0031810D0
|
|
Novel intermediates for chiral scaffolds
|
|
GB0031808D0
|
|
Chiral scaffolds and their preparation
|
|
GB0028881D0
|
|
Process for the preparation of endo-5-norbornene-2-ol
|
|
GB0027198D0
|
|
Diastereomerically enriched amino acids
|
